IE
RNAC icon

Israel Englander’s Cartesian Therapeutics RNAC Stock Holding History

Israel Englander’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,667
Closed -$905K – 7021
2021
Q1 		$905K Buy
+6,667
New +$828K ﹤0.01% 4314

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Israel Englander's RNAC Position: Q2 2026 in Review

Israel Englander increased its Cartesian Therapeutics (RNAC) stake by 9% in Q2 2026, buying an estimated $189K and bringing the position to 309,887 shares worth $3.23M. The position accounts for ﹤0.01% of the portfolio, ranked #3396.

Israel Englander first reported a position in RNAC in Q2 2016 and has held it in 32 quarters since. The position peaked at $7.95M in Q3 2022. 94 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • Israel Englander held 309,887 shares of Cartesian Therapeutics worth $3.23M as of Q2 2026.
  • Israel Englander bought 25,570 Cartesian Therapeutics shares in Q2 2026, an estimated $189K.
  • Cartesian Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3396 holding.
  • Israel Englander first reported a position in Cartesian Therapeutics in Q2 2016 and has held it in 32 quarters since.
  • Israel Englander's Cartesian Therapeutics position peaked at $7.95M in Q3 2022.
  • 94 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.